FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 143 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Repurposing radiotherapy drugs could give immunotherapy a boost November 11, 2022 First immunotherapy approved for cervical cancer in England and Scotland May 16, 2023 Hiding in plain sight: How we can use immune cells to... February 9, 2023 Cómo pueden sobrellevar la ansiedad provocada por una exploración las personas... August 4, 2022 Load more HOT NEWS 5 questions the NHS Workforce Plan for England needs to answer People who’ve had radiotherapy shape our new policy calls Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak A Novel Model Helps Better Predict Risk of Cancer Development in...
